^
    Back
    Association details:
    Biomarker:TP53 R273H
    Cancer:Triple Negative Breast Cancer
    Drug:prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Drug Resist
    Title:

    EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer

    Published date:
    12/05/2020
    Excerpt:
    Prexasertib effectively induced cell death at nanomolar concentrations for most TNBC cell lines, including BRCA mutated HCC1937 and MX-1...The highest sensitivity to prexasertib was observed in MX-1 cells (orange line, IC50, 5.7 nmol/L), while MDA-468 cells were highly resistant (blue line, IC50, 105 nmol/L).
    DOI:
    10.20517/cdr.2020.73